Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to-earnings-to-growth (PEG) ratio of 0.4. PEGs below 1 are generally ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

The stock carries a hefty premium, but it is justified by the company's growth and the size of the market for GLP-1s. Eli Lilly's Q1 report ... maintaining its revenue forecast of $58 billion ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the ... by its 2025 earnings forecast of $22.50 per share ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

and Eli Lilly maintained their buy rating. Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and ...

Looking ahead, the company maintained its sales forecast for revenue ... That makes Eli Lilly a buy in my book. The Motley Fool Stock Advisor analyst team just identified what they believe are ...

Eli Lilly's Q1 numbers showed strong revenue and earnings growth, driven by its GLP-1 offerings. The company's 2025 outlook disappointed investors, however, leading to the decline. The stock ...

While maintaining its revenue forecast ... Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t ...